scholarly journals Advances in Immunotherapy and Molecular Targeted Therapy for Castration Resistant Prostate Cancer

2020 ◽  
Vol 4 (3) ◽  
pp. 67
Author(s):  
Hai Hao ◽  
Pan Wenhai
Keyword(s):  
Prostate Cancer ◽  
Targeted Therapy ◽  
Molecular Targeted Therapy ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?

2019 ◽  
Vol 71 (5) ◽  
Author(s):  
Juan Gómez Rivas ◽  
Diego M. Carrion ◽  
Mario Alvarez-Maestro ◽  
Xavier Cathelineau ◽  
Rafael Sanchez-Salas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Targeted Therapy ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer

2021 ◽  
Vol 14 ◽  
Author(s):  
Jinku Zhang ◽  
Jirui Sun ◽  
Sahar Bakht ◽  
Waseem Hassan
Keyword(s):  
Prostate Cancer ◽  
Clinical Trials ◽  
Molecular Targeted Therapy ◽  
Abiraterone Acetate ◽  
Gonadotropin Releasing Hormone ◽  
Castration Resistant Prostate Cancer ◽  
Future Prospects ◽  
The Past ◽  
Castration Resistant ◽  
Previous Decade

: Prostate cancer (PC) is a rapidly increasing ailment worldwide. The previous decade has observed a rapid advancement in PC therapies that was evident from the number of FDA approvals during this phase. Androgen deprivation therapies (ADT) have traditionally remained a mainstay for the management of PCs, but the past decade has experienced the emergence of newer classes of drugs that can be used with or without the administration of ADT. FDA approved poly (ADP-ribose) polymerase inhibitors (PARPi), such as olaparib and rucaparib, after successful clinical trials against gene-mutated metastatic castration-resistant prostate cancer. Furthermore, drugs like apalutamide, darolutamide, and enzalutamide with an androgen-targeted mechanism of action have manifested superior results in non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-sensitive prostate cancer (mCSPC), and metastatic castration-resistant prostate cancer (mCRPC), respectively, with or without previously administered docetaxel. Relugolix, an oral gonadotropin-releasing hormone antagonist, and a combination of abiraterone acetate plus prednisone were also approved by FDA after a successful trial in advanced PC and mCRPC, respectively. This review aims to analyze the FDA-approved agents in PC during the last decade and provide a summary of their clinical trials. It also presents an overview of the ongoing progress of prospective molecules still under trial.

New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations

2018 ◽  
Vol 36 (6) ◽  
pp. 985-998 ◽  
Author(s):  
Elisabetta Bigagli ◽  
Cristina Luceri ◽  
Maria De Angioletti ◽  
Konstantin Chegaev ◽  
Mario D’Ambrosio ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Targeted Therapy ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Maria Massaro ◽  
Giuseppe Facondo ◽  
Gianluca Vullo ◽  
Anna Maria Aschelter ◽  
Alessandro Rossi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Androgen Receptor ◽  
Targeted Therapy ◽  
Progression Free Survival ◽  
Conformal Radiotherapy ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Free Survival ◽  
Castration Resistant

ObjectivesTo investigate whether radiotherapy as metastasis-directed therapy (MDT) on oligo-progressive sites in metastatic castration-resistant prostate cancer (mCRPC) patients during treatment with androgen receptor-targeted therapy (ARTT) may lead to control resistant lesions, prolonging ARTT. We analysed progression free survival, overall survival and prognostic parameters that can identify patients that best suit to this approach.Patients and MethodsRetrospective analysis of a total of 67 lesions in 42 mCRPC patients treated with ablative or palliative RT to oligoprogressive lesions during ARTT. Twenty-eight patients (67%) underwent ARTT with Abiraterone acetate and 14 patients (33%) underwent ARTT with Enzalutamide. Median time between the start of ADT and ARTT beginning was 50.14 months (range 3.37-219 months). We treated 58 lesions (87%) with 3D conformal radiotherapy (3DCRT) and nine lesions (13%) with stereotactic body radiotherapy (SBRT). The Kaplan Meier method was used to assess the median overall survival (OS) and the progression-free survival (PFS).ResultsMedian follow-up was 28 months (range 3-82 months). Median OS was 32.5 months (95% CI 25.77-39.16), 1 and 2-year OS were 71.6% and 64.1%, respectively. Median PFS was 19,8 months (95% CI 11.34–28.31), 1 and 2-year PFS were 67.2% and 47.4%, respectively. Median OS for patients that underwent radiotherapy before 6 months from the start of ARTT was 23.4 months (95% CI 2.04-44.89) and 45.5 months (95% CI 31.19-59.8) for patients that underwent radiotherapy after 6 months (p = 0.009).ConclusionLocal ablative radiation therapy directed to progressive metastasis is a non-invasive, well tolerated treatment with efficacy on prolonging clinical benefit of systemic therapies with ARTT. Patients who underwent RT >6 months from the start of ARTT presented a statistically better OS and PFS compared with patients who underwent radiotherapy <6 months from the start of ARTT.

Sign in / Sign up

Export Citation Format

Share Document